본문 바로가기

ICH

ICH Q10

Pharmaceutical Quality System

Current Step 4 version dated 4 June 2008

조항 목차

  1. 1PHARMACEUTICAL QUALITY SYSTEM
  2. 1.1Introduction
  3. 1.2Scope
  4. 1.3Relationship of ICH Q10 to Regional GMP Requirements, ISO Standards and ICH Q7 Regional GMP requirements, the ICH Q7 Guideline, “Good Manuf…
  5. 1.4Relationship of ICH Q10 to Regulatory Approaches Regulatory approaches for a specific product or manufacturing facility should be commensur…
  6. 1.5ICH Q10 Objectives
  7. 1.5.1Achieve Product Realisation
  8. 1.5.2Establish and Maintain a State of Control To develop and use effective monitoring and control systems for process performance and product q…
  9. 1.5.3Facilitate Continual Improvement
  10. 1.6Enablers: Knowledge Management and Quality Risk Management Use of knowledge management and quality risk management will enable a company to…
  11. 1.6.1Knowledge Management
  12. 1.6.2Quality Risk Management
  13. 1.7Design and Content Considerations
  14. 1.8Quality Manual
  15. 2MANAGEMENT RESPONSIBILITY
  16. 2.1Management Commitment
  17. 2.2Quality Policy
  18. 2.3Quality Planning
  19. 2.4Resource Management
  20. 2.5Internal Communication
  21. 2.6Management Review
  22. 2.7Management of Outsourced Activities and Purchased Materials The pharmaceutical quality system, including the management responsibilities de…
  23. 2.8Management of Change in Product Ownership When product ownership changes, (e.g., through acquisitions) management should consider the compl…
  24. 3CONTINUAL IMPROVEMENT OF PROCESS PERFORMANCE AND PRODUCT QUALITY
  25. 3.1Lifecycle Stage Goals
  26. 3.1.1Pharmaceutical Development
  27. 3.1.2Technology Transfer
  28. 3.1.3Commercial Manufacturing
  29. 3.1.4Product Discontinuation
  30. 3.2Pharmaceutical Quality System Elements The elements described below might be, required in part under regional GMP regulations. However, the…
  31. 3.2.1Process Performance and Product Quality Monitoring System Pharmaceutical companies should plan and execute a system for the monitoring of p…
  32. 3.2.2Corrective Action and Preventive Action (CAPA) System The pharmaceutical company should have a system for implementing corrective actions a…
  33. 3.2.3Change Management System
  34. 3.2.4Management Review of Process Performance and Product Quality Management review should provide assurance that process performance and produc…
  35. 4CONTINUAL IMPROVEMENT OF THE PHARMACEUTICAL QUALITY SYSTEM
  36. 4.1Management Review of the Pharmaceutical Quality System Management should have a formal process for reviewing the pharmaceutical quality sys…
  37. 4.2Monitoring of Internal and External Factors Impacting the Pharmaceutical Quality System Factors monitored by management can include: (a) Em…
  38. 4.3Outcomes of Management Review and Monitoring The outcome of management review of the pharmaceutical quality system and monitoring of intern…
  39. 5GLOSSARY
  40. Annex 1Annex 1
  41. Annex 2Annex 2
표지·목차 원문

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

ICH HARMONISED TRIPARTITE GUIDELINE

PHARMACEUTICAL QUALITY SYSTEM Q10

Current Step 4 version dated 4 June 2008

This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.

Q10 Document History

Code History Date Q10 Approval by the Steering Committee under Step 2 and release 9 May for public consultation. 2007

Current Step 4 version

Q10 Approval by the Steering Committee under Step 4 and 4 June recommendation for adoption to the three ICH regulatory 2008 bodies.

PHARMACEUTICAL QUALITY SYSTEM

ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 4 June 2008, this guideline is recommended for adoption to the three regulatory parties to ICH

TABLE OF CONTENTS

1. PHARMACEUTICAL QUALITY SYSTEM ........................................................ 1

1.1 Introduction ............................................................................................................. 1

1.2 Scope ........................................................................................................................ 1

1.3 Relationship of ICH Q10 to Regional GMP Requirements, ISO Standards and ICH Q7 ..................................................................................................................... 2

1.4 Relationship of ICH Q10 to Regulatory Approaches .............................................. 2

1.5 ICH Q10 Objectives ................................................................................................. 2

1.5.1 Achieve Product Realisation ........................................................................ 2

1.5.2 Establish and Maintain a State of Control ................................................. 3

1.5.3 Facilitate Continual Improvement ............................................................... 3

1.6 Enablers: Knowledge Management and Quality Risk Management ..................... 3

1.6.1 Knowledge Management .............................................................................. 3

1.6.2 Quality Risk Management ........................................................................... 3

1.7 Design and Content Considerations ....................................................................... 3

1.8 Quality Manual ....................................................................................................... 4

2. MANAGEMENT RESPONSIBILITY .................................................................. 4

2.1 Management Commitment...................................................................................... 4

2.2 Quality Policy .......................................................................................................... 5

2.3 Quality Planning ..................................................................................................... 5

2.4 Resource Management ............................................................................................ 5

2.5 Internal Communication ......................................................................................... 6

2.6 Management Review ............................................................................................... 6

2.7 Management of Outsourced Activities and Purchased Materials .......................... 6

2.8 Management of Change in Product Ownership ...................................................... 6

i

3. CONTINUAL IMPROVEMENT OF PROCESS PERFORMANCE AND PRODUCT QUALITY ........................................................................................... 7

3.1 Lifecycle Stage Goals ............................................................................................... 7

3.1.1 Pharmaceutical Development....................................................................... 7

3.1.2 Technology Transfer ..................................................................................... 7

3.1.3 Commercial Manufacturing ......................................................................... 7

3.1.4 Product Discontinuation .............................................................................. 7

3.2 Pharmaceutical Quality System Elements ............................................................. 7

3.2.1 Process Performance and Product Quality Monitoring System .................. 8

3.2.2 Corrective Action and Preventive Action (CAPA) System ............................ 9

3.2.3 Change Management System ..................................................................... 10

3.2.4 Management Review of Process Performance and Product Quality ......... 11

4. CONTINUAL IMPROVEMENT OF THE PHARMACEUTICAL QUALITY SYSTEM ................................................................................................................ 11

4.1 Management Review of the Pharmaceutical Quality System .............................. 11

4.2 Monitoring of Internal and External Factors Impacting the Pharmaceutical Quality System ...................................................................................................... 12

4.3 Outcomes of Management Review and Monitoring .............................................. 12

5. GLOSSARY .......................................................................................................... 13

Annex 1:Potential Opportunities to Enhance Science and Risk Based Regulatory Approaches ........................................................................................................... 16

Annex 2:Diagram of the ICH Q10 Pharmaceutical Quality System Model ...................... 17

ii PHARMACEUTICAL QUALITY SYSTEM

출처: International Council for Harmonisation (ICH) · © ICH. Per the legal notice in each guideline, the document may be used, reproduced and distributed provided ICH's copyright is acknowledged; any adaptation or translation must be labelled as such and must not imply ICH endorsement. · 수집일 2026-11-15

Weekly Newsletter

이런 지적, 매주 월요일 한국어로 받아보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

매주 월요일 발송 · 구독 신청 시 확인 메일이 발송됩니다 · 수신거부는 모든 메일 하단에서 가능합니다.